Identification of cardiovascular and molecular prognostic factors for the morbidity and mortality in COVID-19-sepsis (ICROVID): Protocol for a prospective multi-centre cohort study

<h4>Introduction</h4> Severe COVID-19 constitutes a form of viral sepsis. Part of the specific pathophysiological pattern of this condition is the occurrence of cardiovascular events. These include pulmonary embolism, arrhythmias and cardiomyopathy as manifestations of extra-pulmonary or...

Full description

Bibliographic Details
Main Authors: Charles Neu, Philipp Baumbach, André Scherag, Andreas Kortgen, Juliane Götze, Sina M. Coldewey
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165863/?tool=EBI
_version_ 1828782204706095104
author Charles Neu
Philipp Baumbach
André Scherag
Andreas Kortgen
Juliane Götze
Sina M. Coldewey
author_facet Charles Neu
Philipp Baumbach
André Scherag
Andreas Kortgen
Juliane Götze
Sina M. Coldewey
author_sort Charles Neu
collection DOAJ
description <h4>Introduction</h4> Severe COVID-19 constitutes a form of viral sepsis. Part of the specific pathophysiological pattern of this condition is the occurrence of cardiovascular events. These include pulmonary embolism, arrhythmias and cardiomyopathy as manifestations of extra-pulmonary organ dysfunction. Hitherto, the prognostic impact of these cardiovascular events and their predisposing risk factors remains unclear. This study aims to explore this question in two cohorts of viral sepsis–COVID-19 and influenza–in order to identify new theragnostic strategies to improve the short- and long-term outcome of these two diseases. <h4>Methods and analysis</h4> In this prospective multi-centre cohort study, clinical assessment will take place during the acute and post-acute phase of sepsis and be complemented by molecular laboratory analyses. Specifically, echocardiography and cardiovascular risk factor documentation will be performed during the first two weeks after sepsis onset. Aside from routine haematological and biochemical laboratory tests, molecular phenotyping will comprise analyses of the metabolome, lipidome and immune status. The primary endpoint of this study is the difference in 3-month mortality of patients with and without septic cardiomyopathy in COVID-19 sepsis. Patients will be followed up until 6 months after onset of sepsis via telephone interviews and questionnaires. The results will be compared with a cohort of patients with influenza sepsis as well as previous cohorts of patients with bacterial sepsis and healthy controls. <h4>Ethics and dissemination</h4> Approval was obtained from the Ethics Committee of the Friedrich Schiller University Jena (2020-2052-BO). The results will be published in peer-reviewed journals and presented at appropriate conferences. <h4>Trial registration</h4> DRKS00024162.
first_indexed 2024-12-11T17:45:03Z
format Article
id doaj.art-da34412a14ab4febb6e7ec062fedfd9b
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-11T17:45:03Z
publishDate 2022-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-da34412a14ab4febb6e7ec062fedfd9b2022-12-22T00:56:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01176Identification of cardiovascular and molecular prognostic factors for the morbidity and mortality in COVID-19-sepsis (ICROVID): Protocol for a prospective multi-centre cohort studyCharles NeuPhilipp BaumbachAndré ScheragAndreas KortgenJuliane GötzeSina M. Coldewey<h4>Introduction</h4> Severe COVID-19 constitutes a form of viral sepsis. Part of the specific pathophysiological pattern of this condition is the occurrence of cardiovascular events. These include pulmonary embolism, arrhythmias and cardiomyopathy as manifestations of extra-pulmonary organ dysfunction. Hitherto, the prognostic impact of these cardiovascular events and their predisposing risk factors remains unclear. This study aims to explore this question in two cohorts of viral sepsis–COVID-19 and influenza–in order to identify new theragnostic strategies to improve the short- and long-term outcome of these two diseases. <h4>Methods and analysis</h4> In this prospective multi-centre cohort study, clinical assessment will take place during the acute and post-acute phase of sepsis and be complemented by molecular laboratory analyses. Specifically, echocardiography and cardiovascular risk factor documentation will be performed during the first two weeks after sepsis onset. Aside from routine haematological and biochemical laboratory tests, molecular phenotyping will comprise analyses of the metabolome, lipidome and immune status. The primary endpoint of this study is the difference in 3-month mortality of patients with and without septic cardiomyopathy in COVID-19 sepsis. Patients will be followed up until 6 months after onset of sepsis via telephone interviews and questionnaires. The results will be compared with a cohort of patients with influenza sepsis as well as previous cohorts of patients with bacterial sepsis and healthy controls. <h4>Ethics and dissemination</h4> Approval was obtained from the Ethics Committee of the Friedrich Schiller University Jena (2020-2052-BO). The results will be published in peer-reviewed journals and presented at appropriate conferences. <h4>Trial registration</h4> DRKS00024162.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165863/?tool=EBI
spellingShingle Charles Neu
Philipp Baumbach
André Scherag
Andreas Kortgen
Juliane Götze
Sina M. Coldewey
Identification of cardiovascular and molecular prognostic factors for the morbidity and mortality in COVID-19-sepsis (ICROVID): Protocol for a prospective multi-centre cohort study
PLoS ONE
title Identification of cardiovascular and molecular prognostic factors for the morbidity and mortality in COVID-19-sepsis (ICROVID): Protocol for a prospective multi-centre cohort study
title_full Identification of cardiovascular and molecular prognostic factors for the morbidity and mortality in COVID-19-sepsis (ICROVID): Protocol for a prospective multi-centre cohort study
title_fullStr Identification of cardiovascular and molecular prognostic factors for the morbidity and mortality in COVID-19-sepsis (ICROVID): Protocol for a prospective multi-centre cohort study
title_full_unstemmed Identification of cardiovascular and molecular prognostic factors for the morbidity and mortality in COVID-19-sepsis (ICROVID): Protocol for a prospective multi-centre cohort study
title_short Identification of cardiovascular and molecular prognostic factors for the morbidity and mortality in COVID-19-sepsis (ICROVID): Protocol for a prospective multi-centre cohort study
title_sort identification of cardiovascular and molecular prognostic factors for the morbidity and mortality in covid 19 sepsis icrovid protocol for a prospective multi centre cohort study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165863/?tool=EBI
work_keys_str_mv AT charlesneu identificationofcardiovascularandmolecularprognosticfactorsforthemorbidityandmortalityincovid19sepsisicrovidprotocolforaprospectivemulticentrecohortstudy
AT philippbaumbach identificationofcardiovascularandmolecularprognosticfactorsforthemorbidityandmortalityincovid19sepsisicrovidprotocolforaprospectivemulticentrecohortstudy
AT andrescherag identificationofcardiovascularandmolecularprognosticfactorsforthemorbidityandmortalityincovid19sepsisicrovidprotocolforaprospectivemulticentrecohortstudy
AT andreaskortgen identificationofcardiovascularandmolecularprognosticfactorsforthemorbidityandmortalityincovid19sepsisicrovidprotocolforaprospectivemulticentrecohortstudy
AT julianegotze identificationofcardiovascularandmolecularprognosticfactorsforthemorbidityandmortalityincovid19sepsisicrovidprotocolforaprospectivemulticentrecohortstudy
AT sinamcoldewey identificationofcardiovascularandmolecularprognosticfactorsforthemorbidityandmortalityincovid19sepsisicrovidprotocolforaprospectivemulticentrecohortstudy